FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. (Articolo in rivista) (literal)

Anno

• 2015-01-01T00:00:00+01:00 (literal)

Alternative label

• F Morra, C Luise, F Merolla, I Poser, R Visconti, H Inuzuka, G Ilardi, G Guggino, R Monaco, D Colecchia, G Monaco, A Cerrato, M Chiariello, Krista Denning, Pier Paolo Claudio, S Staibano and A Celetti (2015)
  FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.
  in Oncotarget
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• F Morra, C Luise, F Merolla, I Poser, R Visconti, H Inuzuka, G Ilardi, G Guggino, R Monaco, D Colecchia, G Monaco, A Cerrato, M Chiariello, Krista Denning, Pier Paolo Claudio, S Staibano and A Celetti (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• March 30 (literal)

Rivista

• Oncotarget (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• IEOS, CNR (literal)

Titolo

• FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. (literal)

Abstract

• CCDC6 gene product is a pro-apoptotic protein substrate of ATM, whose loss or inactivation enhances tumour progression. In primary tumours, the impaired function of CCDC6 protein has been ascribed to CCDC6 rearrangements and to somatic mutations in several neoplasia. Recently, low levels of CCDC6 protein, in NSCLC, have been correlated with tumor prognosis. However, the mechanisms responsible for the variable levels of CCDC6 in primary tumors have not been described yet. We show that CCDC6 turnover is regulated in a cell cycle dependent manner. CCDC6 undergoes a cyclic variation in the phosphorylated status and in protein levels that peak at G2 and decrease in mitosis. The reduced stability of CCDC6 in the M phase is dependent on mitotic kinases and on degron motifs that are present in CCDC6 and direct the recruitment of CCDC6 to the FBXW7 E3 Ubl. The de-ubiquitinase enzyme USP7 appears responsible of the fine tuning of the CCDC6 stability, affecting cells behaviour and drug response. Thus, we propose that the amount of CCDC6 protein in primary tumors, as reported in lung, may depend on the impairment of the CCDC6 turnover due to altered protein-protein interaction and post-translational modifications and may be critical in optimizing personalized therapy. (literal)

Prodotto di

• Istituto per l'endocrinologia e l'oncologia \"Gaetano Salvatore\" (IEOS) (Istituto)

Autore CNR

• MARIO CHIARIELLO (Persona)
• ROBERTA VISCONTI (Unità di personale interno)
• ANGELA CELETTI (Persona)
• ANIELLO CERRATO (Persona)

Incoming links:

Autore CNR di

• ANGELA CELETTI (Persona)
• ANIELLO CERRATO (Persona)
• ROBERTA VISCONTI (Unità di personale interno)
• MARIO CHIARIELLO (Persona)

Prodotto

• Istituto per l'endocrinologia e l'oncologia \"Gaetano Salvatore\" (IEOS) (Istituto)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Oncotarget (Rivista)